{
  "ticker": "TTX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971722",
  "id": "02971722",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0845",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1nbnjz36c20.pdf",
  "summary": "### **Tetratherix Limited (ASX: TTX) - Material Information Summary**  \n\n#### **Key Highlights (Appendix 4C & Quarterly Activities Report \u2013 Q4 FY25)**  \n- **Licensing Agreement with BioOptix**  \n  - Strategic exclusive license for **ophthalmic viscoelastic device (OVD)** development.  \n  - **Estimated OVD market:** ~USD 700M globally.  \n  - Tetratherix to become **minority shareholder** in BioOptix.  \n  - **Milestone payments expected from FY26.**  \n  - BioOptix funds **FDA approval costs**; Tetratherix to manufacture post-commercialization (~1M units/5-year minimum supply).  \n\n- **Tutelix FDA Progress (50% JV)**  \n  - **Pre-submission meeting completed** \u2013 **Class II device** classification confirmed.  \n  - **510(k) clearance on track for FY28** (prostate spacer).  \n\n- **ASX Listing & Capital Raise**  \n  - **IPO proceeds: $25M (primary capital)** at **$2.88/share** (implied **$145M market cap**).  \n  - **No secondary issuance.**  \n\n- **Financial Position (30 June 2025)**  \n  - **Cash balance: $29.3M** (zero debt).  \n  - Q4 cash outflow: **$3.9M** (IPO costs + R&D).  \n\n- **Upcoming Catalysts (Q1/Q2 FY26)**  \n  - **Tutelix first-in-human trial** (Gold Coast, QLD).  \n  - **FDA 510(k) clearances targeted for Tegenix/TegeEOS (H2 FY26).**  \n  - **TetraDerm Phase 2 Cohort 2 recruitment** (face/neck incisions).  \n\n*No other material information identified.*",
  "usage": {
    "prompt_tokens": 5306,
    "completion_tokens": 398,
    "total_tokens": 5704,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:56:31.890773"
}